Summary of Key Points Core Viewpoint - This week, 234 listed companies disclosed institutional research records, with nearly 40% of the companies experiencing positive stock performance, indicating a strong interest from institutional investors in various sectors [1][2]. Group 1: Institutional Research and Stock Performance - 32.19% increase in stock price for Haibo Sichuang during the week [1] - 25.03% increase in stock price for Xin Zuo Biao, marking its first board appearance [1] - 20.81% increase in stock price for World [1] Group 2: Notable Companies and Their Developments - Jingzhida (688627) received attention from 138 institutions, with a stock price increase of 17.68%. The company focuses on display panels and semiconductor testing equipment, highlighting advancements in storage testing and AI-related product lines [2] - Xintai's stock rose 15.81% after hosting a roadshow with 77 institutional investors. The company specializes in pharmaceuticals and medical devices, with over 80% of revenue from its formulation business [2] - Mengke Pharmaceutical hosted 66 institutions and announced a change in its controlling shareholder, planning to raise up to 1.033 billion yuan through a private placement [2] Group 3: Strategic Partnerships and Collaborations - Gaowei Da attracted 40 institutional investors due to a strategic partnership with Ant Group, focusing on AI and big data in financial technology [2] - The partnership aims to leverage both companies' strengths to enhance service capabilities and technology solutions in the financial sector [2]

Group 1 - A total of 234 listed companies disclosed institutional research records this week, with nearly 40% of them achieving positive stock returns [1] - The stock price of Jingzhida (688627) increased by 17.68% after receiving 138 institutional inquiries, focusing on its storage testing and semiconductor testing equipment [1][2] - Xintai's stock rose by 15.81% after hosting a roadshow with 77 institutional investors, with its core revenue source being over 80% from its formulation business [2] Group 2 - Mengke Pharmaceutical announced a stock issuance plan at a price of 6.3 yuan per share, raising up to 1.033 billion yuan, with Haiqing Pharmaceutical becoming the controlling shareholder [3] - Haiqing Pharmaceutical will leverage its experience in raw material drug development to enhance Mengke's product cost efficiency and profitability [3] - Gaowei Technology received attention from over 40 institutions due to its strategic partnership with Ant Group, focusing on AI and financial technology [4][5]

Wind数据显示，截至9月26日16时，本周共计234家上市公司披露机构调研纪要。从赚钱效应来看，本周近四成机构调研公司股价实现正收益，其中海博 思创周内股价累计上涨32.19%，新坐标周内迎来首板，上涨25.03%，沃尔德股价累计上涨20.81%。冰轮环境本周举行三场调研活动，潍柴动力、章源钨 业、金力永磁、宁波银行等10家公司周内举办两场调研。 从热门调研标的来看，精智达（688627）本周接受138家机构调研，周内股价涨幅为17.68%。精智达主营业务聚焦显示面板与半导体测试设备两大核心赛 道。在调研中，机构重点询问该公司存储测试业务、算力芯片测试业务、探针卡业务等多项业务进展。 | 30分 60分 日 K 分时 | 周K 目K 叠加 ▼前复权 ▼ 真他 ▼ | 1 50 | 精智达1(68862 | | --- | --- | --- | --- | | | | 180 00 | | | | | 100.00 | | | | | 90.00 | | | | | 80.00 | | | | | 70.00 | | | | 688627 区间统计 | | | | 开始时间: 2025/09/01 ◀ ▶ ...

Group 1 - As of September 26, 234 listed companies disclosed institutional research minutes, with nearly 40% of these companies experiencing positive stock returns during the week [1] - Notable stock price increases included Haibosi Chuang up 32.19%, New Coordinates up 25.03%, and World up 20.81% [1] - Jingzhida (688627) received attention from 138 institutions, with a stock price increase of 17.68%, focusing on display panels and semiconductor testing equipment [1] Group 2 - Jingzhida's executives reported that the high-speed FT testing machine met its annual goals ahead of schedule, and the aging testing machine is in high demand [3] - The company is strategically expanding its product line to meet AI era demands, focusing on storage, computing power, and human-computer interaction [3] - Xintai, a pharmaceutical company, hosted a roadshow and received 77 institutional investors, with a stock price increase of 15.81% [3] Group 3 - Xintai addressed investor inquiries regarding the impact of geopolitical factors on its U.S. subsidiary and the role of AI in research efficiency [5] - Mengke Pharmaceutical announced a stock issuance plan to raise up to 1.033 billion yuan, with a new controlling shareholder [7] - Mengke's collaboration with Haiqing Pharmaceutical aims to enhance product cost efficiency and profitability through shared expertise in raw material drug development [7] Group 4 - Xinghui Entertainment, Gaoweida, and Dansheng Technology received attention from over 40 institutions, with Gaoweida's partnership with Ant Group being a focal point [9] - The strategic partnership aims to enhance innovation in smart customer acquisition, big data risk control, and AI technology [9] - Gaoweida emphasized its strengths as a leading financial technology company with extensive service networks in the financial sector [9]

Group 1 - A total of 234 listed companies disclosed institutional research minutes this week, with nearly 40% of them achieving positive stock returns [1] - Companies such as Haibo Sichuang, New Coordinates, and World achieved significant stock price increases of 32.19%, 25.03%, and 20.81% respectively [1] - Jingzhida received attention from 138 institutions, with a stock price increase of 17.68%, focusing on its core business in display panels and semiconductor testing equipment [1][2] Group 2 - Jingzhida's executives highlighted the strong demand for aging testing machines and their advantages in advanced temperature control and mass production experience [1][2] - Xinlitai hosted a roadshow in Shenzhen, attracting 77 institutional investors and achieving a stock price increase of 15.81%, with a focus on its pharmaceutical and medical device business [2] - Mengke Pharmaceutical announced a private placement plan to raise up to 1.033 billion yuan, with Nanjing Haiqing Pharmaceutical becoming the controlling shareholder [3] Group 3 - Highwei Technology received attention from over 40 institutions due to its strategic partnership with Ant Group, focusing on AI and financial technology [4] - Highwei emphasized the synergy between its extensive service network in financial institutions and Ant Group's technological advantages, aiming for a dual empowerment model [4] - The procurement plan will align with project implementation, prioritizing key modules such as credit fraud prevention and AI traffic operations [4]

截至9月19日，誉衡药业股东户数10.57万，较上期减少1.03%；人均流通股19831股，较上期增加 1.04%。2025年1月-6月，誉衡药业实现营业收入11.00亿元，同比减少9.97%；归母净利润1.34亿元，同 比增长7.56%。 分红方面，誉衡药业A股上市后累计派现6.92亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年6月30日，誉衡药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股3123.30万股，为新进股东。 责任编辑：小浪快报 9月24日，誉衡药业涨0.31%，成交额1.30亿元。两融数据显示，当日誉衡药业获融资买入额1047.10万 元，融资偿还1127.01万元，融资净买入-79.91万元。截至9月24日，誉衡药业融资融券余额合计4.09亿 元。 融资方面，誉衡药业当日融资买入1047.10万元。当前融资余额4.09亿元，占流通市值的5.81%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，誉衡药业9月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量100.00股，融券余额321.00元，超过近 ...